Trial reportObstetrics and gynecology2026
Diabetes Testing Immediately Postpartum After Gestational Diabetes Mellitus: A Randomized Controlled Trial.
Trial report in Obstetrics and gynecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05909046 (A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) - Follow up Study: Patient Perspectives on Postpartum Interventions to Improve Future Maternal CARdiovascular hEalth After Gestational Diabetes (PP CARE)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivePatient receipt of outpatient postpartum glucose testing after gestational diabetes mellitus (GDM) remains suboptimal. We conducted a randomized controlled trial (RCT) to determine whether the frequency of receiving a postpartum oral glucose tolerance test (OGTT) differed depending on whether the test was planned for the inpatient or outpatient setting.
methodsDIP (Diabetes Testing Immediately Postpartum) was a pragmatic, nonblinded RCT. Participants were eligible if they received prenatal care and had a GDM diagnosis. After delivery, individuals were randomized in a 1:1 ratio to receive an OGTT either inpatient before delivery discharge (intervention) or outpatient within 12 weeks of birth (standard care). The primary outcome was completion of a fasting 2-hour 75-g OGTT by 12 weeks postpartum or less. Secondary outcomes included participant satisfaction per the adapted DTSQ (Diabetes Treatment Satisfaction Questionnaire) and diagnosis of prediabetes or type 2 diabetes. Based on an estimated baseline testing rate of 52% and a treatment effect of at least 50%, a sample size of 104 participants was required with 80% power and a two-sided α of 0.05.
resultsA total of 104 individuals with GDM were enrolled (52 intervention, 52 standard care). Demographics, unmet social needs, and clinical characteristics did not differ according to group assignment. Postpartum visit completion was more than 90% in both groups. The frequency of postpartum diabetes testing was significantly higher in the inpatient group compared with the outpatient group (92.3% vs 26.9%, relative risk 3.43 [95% CI, 2.18-5.40]), as was the median [IQR] score on the DTSQ (35.0 [31.0, 36.0] vs 28.0 [24.0, 32.0], P <.001). Prediabetes or type 2 diabetes was diagnosed among 50.0% in the inpatient group and 21.4% in the outpatient group ( P =.05).
conclusionDiabetes testing before delivery discharge for individuals with GDM resulted in more than a threefold higher completion rate of postpartum glucose testing and greater patient satisfaction compared with outpatient testing. This RCT supports recent guidelines that encourage the option of inpatient postpartum diabetes testing before delivery discharge. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov , NCT05909046.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.